logo

Beyondspring Inc. (BYSI)



Trade BYSI now with
  Date
  Headline
4/3/2018 7:16:15 AM BeyondSpring 2017 Attributable Net Loss $91.8 Mln Vs. Loss $12.0 Mln Prior Year
3/27/2018 7:03:30 AM BeyondSpring Appoints Edward Dongheng Liu As CFO
3/19/2018 8:09:43 AM BeyondSpring Begins Phase 3 Clinical Development For Plinabulin For Prevention Of Chemotherapy-Induced Neutropenia
12/14/2017 8:12:32 AM BeyondSpring Meets Primary Objective In Phase2 Portion Of Phase2/3 Trial With Plinabulin For Prevention Of Docetaxel CIN
11/30/2017 10:02:55 AM BeyondSpring Initiates Phase 2/3 Trial With Plinabulin In China For The Prevention Of Chemotherapy-Induced Neutropenia
11/9/2017 7:31:08 AM BeyondSpring Q3 Net Loss Attributable $15.5 Mln
7/6/2017 8:12:19 AM China FDA Approves CTAs For BeyondSpring’s Second Global Plinabulin Registrational Trial
5/22/2017 4:09:18 PM BeyondSpring Q1 Loss/share $0.12 Vs. Loss $2.66 Year Ago